The steady generic pricing is a tailwind and execution of key launches like gAbraxane for Cipla will determine the path of US sales in 2025.
Paul Black’s 3 thumb rules for identifying great wealth creators
Veteran portfolio manager Paul Black’s investment framework focuses on identifying businesses with competitive advantages that strengthen over time. His three key rules emphasise widening moats,